Biomarkers associated with bronchopulmonary dysplasia/mortality in premature infants

Pediatric Research

Volumn 81, Issue 3, 2017, Pages 519-525

  Balena Borneman, Jessica ^a   Ambalavanan, Namasivayam ^b   Tiwari, Hemant K ^a   Griffin, Russell L ^a   Halloran, Brian ^b   Askenazi, David ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ALBUMIN; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALBINDIN; CHROMIUM; CLUSTERIN; CYSTATIN C; EPIDERMAL GROWTH FACTOR; GLUTATHIONE TRANSFERASE; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; OSTEOACTIVIN; OSTEOPONTIN; TAMM HORSFALL GLYCOPROTEIN; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; VASCULOTROPIN; CLU PROTEIN, HUMAN;

AREA UNDER THE CURVE; ARTICLE; DATA BASE; FEMALE; GESTATIONAL AGE; HUMAN; INFANT; INFANT MORTALITY; INTUBATION; LUNG DYSPLASIA; MAJOR CLINICAL STUDY; MALE; MODEL; ODDS RATIO; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; SMALL FOR DATE INFANT; ALBUMINURIA; BIRTH WEIGHT; MORTALITY; NEONATAL INTENSIVE CARE UNIT; NEWBORN; RISK FACTOR; URINE; VERY LOW BIRTH WEIGHT;

ALBUMINURIA; BIOMARKERS; BIRTH WEIGHT; BRONCHOPULMONARY DYSPLASIA; CLUSTERIN; FEMALE; GESTATIONAL AGE; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, SMALL FOR GESTATIONAL AGE; INFANT, VERY LOW BIRTH WEIGHT; INTENSIVE CARE UNITS, NEONATAL; MALE; ODDS RATIO; RISK FACTORS;

EID: 85016404395     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2016.259     Document Type: Article

References (23)

1. Ambalavanan N, Carlo WA. Bronchopulmonary dysplasia: new insights. Clin Perinatol 2004;31:613-28.
2. Coalson JJ. Pathology of bronchopulmonary dysplasia. Semin Perinatol 2006;30:179-84.
3. Tooley WH. Epidemiology of bronchopulmonary dysplasia. J Pediatr 1979;95(5 Pt 2):851-8.
4. Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527-32.
5. Askenazi D, Patil NR, Ambalavanan N, et al. Acute kidney injury is asso-ciated with bronchopulmonary dysplasia/mortality in premature infants. Pediatr Nephrol 2015;30:1511-8.
6. Askenazi DJ, Koralkar R, Patil N, et al. Acute kidney injury urine bio-markers in very low-birth-weight infants. Clin J Am Soc Nephrol 2016;1: 1527-35.
7. Saeidi B, Koralkar R, Grifn RL, Halloran B, Ambalavanan N, Askenazi DJ. Impact of gestational age, sex, and postnatal age on urine biomarkers in premature neonates. Pediatr Nephrol 2015;30:2037-44.
8. Laughon MM, Langer JC, Bose CL, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am J Respir Crit Care Med 2011;183: 1715-22.
9. Onland W, Debray TP, Laughon MM, et al. Clinical prediction models for bronchopulmonary dysplasia: a systematic review and external validation study. BMC Pediatr 2013;13:207.
10. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol 2002;34:427-31.
11. Koltai T. Clusterin: a key player in cancer chemoresistance and its inhibi-tion. Onco Targets Ter 2014;7:447-56.
12. Sansanwal P, Li L, Sarwal MM. Inhibition of intracellular clusterin attenuates cell death in nephropathic cystinosis. J Am Soc Nephrol 2015;26: 612-25.
13. Lin CC, Tsai P, Sun H Y, et al. Apolipoprotein J, a glucose-upregulated molecular chaperone, stabilizes core and NS5A to promote infectious hepatitis C virus virion production. J Hepatol 2014;61:984-93.
14. Lee YN, Shim YJ, Kang BH, Park JJ, Min BH. Over-expression of human clusterin increases stress resistance and extends lifespan in Drosophila melanogaster. Biochem Biophys Res Commun 2012;420:851-6.
15. Trougakos I P. The molecular chaperone apolipoprotein J/clusterin as a sensor of oxidative stress: implications in therapeutic approaches-a mini-review. Gerontology 2013;59:514-23.
16. Li J Y, Liu J, Jiang J, et al. Calcium oxalate calculi-induced clusterin expression in kidney. Urolithiasis 2015;43:411-8.
17. Girton RA, Sundin DP, Rosenberg ME. Clusterin protects renal tubular epithelial cells from gentamicin-mediated cytotoxicity. Am J Physiol Renal Physiol 2002;282:F703-9.
18. Kwon HS, Kim TB, Lee YS, et al. Clusterin expression level correlates with increased oxidative stress in asthmatics. Ann Allergy Asthma Immunol 2014;112:217-21.
19. Doi K, Ishizu T, Fujita T, Noiri E. Lung injury following acute kidney injury: kidney-lung crosstalk. Clin Exp Nephrol 2011;15:464-70.
20. Ko GJ, Rabb H, Hassoun HT. Kidney-lung crosstalk in the critically ill patient. Blood Purif 2009;28:75-83.
21. Karimi Z, Ketabchi F, Alebrahimdehkordi N, et al. Renal ischemia/reper-fusion against nephrectomy for induction of acute lung injury in rats. Ren Fail. 2016;3:1-16.
22. Faubel S, Shah PB. Immediate consequences of acute kidney injury: the impact of traditional and nontraditional complications on mortality in acute kidney injury. Adv Chronic Kidney Dis 2016;23:179-85.
23. Hong GH, Kwon HS, Moon KA, et al. Clusterin modulates allergic airway infammation by attenuating CCL20-mediated dendritic cell recruitment. J Immunol 2016;196:2021-30.